mTOR inhibitors and diabetes
Authors:
- 1 November 2015
- journal article
- review article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 110 (2) , 101-108
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolismEuropean Journal of Endocrinology, 2014
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialThe Lancet, 2013
- Mechanistic target of rapamycin inhibitors in solid organ transplantationCurrent Opinion in Organ Transplantation, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- The functions of mTOR in ischemic diseasesBMB Reports, 2011
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Defining the Role of mTOR in CancerCancer Cell, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007